
-
Legend Biotech Corporation NasdaqGS:LEGN Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. The company was founded in 2014 and is headquartered in Somerset, New Jersey.
Location: 2101 Cottontail Lane, Somerset, NJ, 08873, United States | Website: https://www.legendbiotech.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
10.02B
Cash
1.005B
Avg Qtr Burn
-65.83M
Short % of Float
4.65%
Insider Ownership
1.33%
Institutional Own.
47.77%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
CARVYKTI (cilta-cel) (ciltacabtagene autoleucel) Details Blood cancer, Cancer, Multiple myeloma | Approved Quarterly sales | |
CARVYKTI (cilta-cel) Details Blood cancer, Cancer, Multiple myeloma | Approved Quarterly sales | |
Phase 3 Data readout | ||
LB2102 Details Cancer, Small cell lung cancer | Phase 1 Data readout | |
LB1901 Details Cancer, T-cell lymphoma | Failed Discontinued |